Recently, the construction project of Zhongke Pharmaceutical’s Overseas R&D Center has successfully passed the acceptance inspection by the Jiangsu Provincial Department of Science and Technology and has officially obtained the project acceptance certificate.
The construction project of Zhongke Pharmaceutical’s Overseas R&D Center was officially approved and initiated in 2022, and was included in the 2022 Special Fund for Science and Technology Programs of Jiangsu Province – International Science and Technology Cooperation Program of the Innovation Support Plan jointly launched by the Jiangsu Provincial Department of Finance and the Jiangsu Provincial Department of Science and Technology. In November 2024, an expert group formed by the Jiangsu Provincial Department of Science and Technology and the Nanjing Municipal Bureau of Science and Technology conducted the acceptance review of the project, which finally passed the acceptance inspection successfully.
The Zhongke Pharmaceutical Overseas R&D Center is an overseas R&D institution under Zhongke Health International (New York) Co., Ltd., a wholly-owned subsidiary established by Nanjing Zhongke Pharmaceutical in the United States in 2017. Since its establishment, the center has focused on the R&D of innovative anti-tumor traditional Chinese medicine drugs in the ganoderma field, and carried out in-depth research on the chemical structures and pharmacology of active ingredients of modern traditional Chinese medicine. Meanwhile, it has gathered innovative talents and advantageous scientific and technological resources from China and the United States to build a localized team for R&D, marketing and services.
In 2019, Zhongke’s Overseas R&D Center launched a clinical research collaboration on Compound Ganoderma Spore Capsules with Memorial Sloan Kettering Cancer Center (MSKCC) in the United States, a prestigious cancer research institution with a long history of more than 130 years and rich experience in clinical management. This multicenter, randomized, double-blind, placebo-controlled parallel clinical study, an intellectual property independently owned by Zhongke, has progressed to Phase Ⅲ and achieved favorable positive results.
In 2020, with the joint efforts of Chinese and American oncology experts from Guang’anmen Hospital of China Academy of Chinese Medical Sciences and MSKCC in the United States, the paper entitled Preliminary Efficacy and Safety Evaluation of Compound Ganoderma Spore Capsules in Maintaining the Quality of Life of Chemotherapy Patients with Non-Small Cell Lung Cancer: A Randomized Placebo-Controlled Trial was published in Integrative Cancer Therapies, an international oncology SCI journal. In the same year, the international cooperation project of “Cooperative Development of Ganoderma Spore Powder Extraction Technology” was approved, securing a total of 1.05 million yuan in financial support including funding from Nanjing’s International Science and Technology Cooperation Project and a grant from the Tengfei Plan of Jiangning Economic and Technological Development Zone.
At present, Zhongke Pharmaceutical’s Overseas R&D Center has more than ten ganoderma-based products under research, among which two independently developed products, Zhongke Coriolus Versicolor and Ganoderma Spores, have made breakthrough progress and been listed in the pharmacy of MSKCC.
The successful acceptance of the Overseas R&D Center project of Zhongke Pharmaceutical marks a new stage in Zhongke Group’s R&D capabilities and innovative cooperation. Going forward, the center will continue to intensify its R&D efforts, draw on international pharmaceutical standards and norms, advance in-depth research on the chemical structures and pharmacology of active ingredients of modern traditional Chinese medicine, and enhance the competitiveness of the modern traditional Chinese medicine industry in the international market.
CN 
EN